Jennifer Curtis connects with Ben Hohn to discuss trends in first launch and partnering, focusing on emerging pharma and changes in strategic decision-making.
Highlights from the episode:
- Emerging pharma is driving industry innovation and a substantial share of total pharma pipeline
- Although Europe is typically considered a more challenging market, emerging pharma companies have seen success both in solo and partnered commercialization efforts
- The success we're seeing emerging pharma have is partly due to ecosystem shifts, for example reduced reliance on acquisition by larger firms at the asset development stage, as well as an increased focus on specialist and orphan assets
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
